Amyloid-beta produced in peripheral organs, specifically the liver, may be implicated in the brain neurodegeneration observed in Alzheimer’s disease, according to a mouse study. The study, “Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype,” was published in PLOS Biology. Deposits of amyloid-beta in the brain are a hallmark of Alzheimer’s.…
Research institutions in North Carolina and Texas have become the newest members of a national network of Alzheimer’s Disease Research Centers (ADRCs), which are at the forefront of research into Alzheimer’s and related dementias. The ADRCs, a project funded by the National Institute on Aging (NIA), have “been at the heart of progress in Alzheimer’s…
Six months of daily supplements of omega-3 increased the levels of two biomarkers of inflammation and nerve damage in the cerebrospinal fluid (CSF) of people with Alzheimer’s disease, according to a post-hoc analysis of data from the OmegAD clinical trial. While these preliminary findings suggest that omega-3 supplements may be associated with higher inflammation and…
AlzeCure Pharma has been granted approval by Swedish regulatory authorities to start its third Phase 1 study of ACD856, the company’s leading therapeutic candidate for Alzheimer’s disease. The study is designed to test multiple ascending doses of the medication, which means that the amount of ACD856 will be increased for each new group of participants.…
Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the agency’s controversial decision to grant accelerated approval to Biogen‘s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. U.S. Rep. Frank Pallone, Jr., chair of the House Committee on Energy and Commerce, and U.S. Rep. Carolyn…
Each September, people from around the globe come together to heighten awareness of Alzheimer’s disease and push back against stigmas around dementia. This year marks a decade of advocacy, as supporters observe the 10th World Alzheimer’s Month. Throughout the month, patients, caregivers, and advocates will share messages and stories on social media, attend activities put…
Using a genetic approach that can “read” the entire human genetic signature, researchers have identified 13 gene variants — or mutations — associated with Alzheimer’s disease risk whose functions are related to neuronal or nerve cell development and connections. Moreover, the scientists said their study establishes new genetic links to neuroplasticity, or the brain’s ability…
Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people with Alzheimer’s disease, showed evidence of infection by Porphyromonas gingivalis (P. gingivalis), according to a new analysis. In particular, all patients analyzed at the beginning of the study who had available data on their cerebrospinal fluid —…
A partnership agreement will allow INmune Bio to continue using biomarker imaging technology by Imeka in future clinical trials evaluating XPro1595, the company’s investigational therapy for Alzheimer’s disease. INmune Bio is planning to initiate a Phase 2 study of XPro1595 in Alzheimer’s patients this year, it stated in a press release. The agreement follows early evidence from its…
I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech company’s announcement follows the recent approval of an investigational new drug (IND) application for Protollin by the U.S. Food and Drug Administration (FDA). “Advancing Protollin into clinic is a critical milestone in the search to…
